Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
about
Determinants of Affinity and Proteolytic Stability in Interactions of Kunitz Family Protease Inhibitors with MesotrypsinThe P 2 ′ residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activitySequence and conformational specificity in substrate recognition: several human Kunitz protease inhibitor domains are specific substrates of mesotrypsin.Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as SubstratesPRSS3 is a prognostic marker in invasive ductal carcinoma of the breast.Small molecule inhibitors of mesotrypsin from a structure-based docking screen.Identification of C16orf74 as a marker of progression in primary non-muscle invasive bladder cancer.Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinomaNoninvasive imaging identifies new roles for cyclooxygenase-2 in choline and lipid metabolism of human breast cancer cellsFinding off-targets, biological pathways, and target diseases for chymase inhibitors via structure-based systems biology approach.CAPC negatively regulates NF-κB activation and suppresses tumor growth and metastasis.Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapyCD105 (Endoglin) exerts prognostic effects via its role in the microvascular niche of paediatric high grade glioma.CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts.SheddomeDB: the ectodomain shedding database for membrane-bound shed markers.PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancerBiochemical and structural insights into mesotrypsin: an unusual human trypsin.Metastasis-associated cell surface oncoproteomics.Novel combination markers for predicting progression of nonmuscle invasive bladder cancer.Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma.Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2.CD109 expression is upregulated in penile squamous cell carcinoma.Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases.Profiling plasma extracellular vesicle by pluronic block-copolymer based enrichment method unveils features associated with breast cancer aggression, metastasis and invasion.Clinical significance and expression of the PRSS3 and Wiskott-Aldrich syndrome protein family verprolin-homologous protein 1 for the early detection of epithelial ovarian cancerMapping protein selectivity landscapes using multi-target selective screening and next-generation sequencing of combinatorial libraries
P2860
Q27664637-EB96C72C-FDE7-4A1E-8A3F-97FF3DE49F68Q27671330-4B658C50-4835-41E8-9386-96D99AA7BEDAQ30367678-6D139296-6D99-4D53-94A0-55A56E044C6CQ30376720-64F97835-0B03-4783-84BD-E399F1AA60E1Q33591558-FFC441DE-949F-4BDB-9751-F381EFA7D914Q33626452-E2B170D8-60E8-4FF2-BBED-09B52F00FD76Q33784739-340872A7-AC59-495F-BCCB-374DFAC36B36Q35022888-EC6B0F1C-2556-4C1F-B90A-A7AAA6D46300Q35112020-7F281979-569E-4B4F-8E49-1155C540DFB9Q35229098-9EF7A6E1-F8B3-4764-9455-E0E86D4EF9FDQ35541785-06DCAF0E-400C-4935-AE02-7076B8EA8770Q35950487-4429A5DC-D524-459C-999E-458AF10B43E3Q36041205-39DB8175-2DC9-433F-B033-75DAC701F532Q36246124-F6CBCCC3-8C7B-49CB-B1BE-AFC90C6AB9B7Q36329547-1F90E679-57CB-4438-92BF-D85A6167FE0CQ36493144-946109E1-691C-4132-9E4C-636836883637Q37180025-0D0B860E-6658-436B-A528-118A1FFD535BQ38060714-6E72D762-922C-4F3A-8684-A3C3E73C0FF4Q38469299-29C14ED8-BE51-4D6E-8627-E57256893D51Q38694104-E24AFEF7-DB0A-4B45-93A7-40AF84D79271Q41535597-41032D0F-1402-4414-9BED-1C7B7B24D003Q43269447-8F38AB4D-AF48-467E-8152-E69AA046C1C2Q52657347-231B8950-343F-44BF-84C3-D3BB676AF37AQ55383954-2FFC6DFA-D4D1-4064-851E-725785B2699CQ56487500-2ADCB90C-7CFB-4C11-AA23-E393EC0D2EBAQ58695396-EC1114E8-017D-408A-89C9-C095D5C4037A
P2860
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@ast
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@en
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@nl
type
label
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@ast
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@en
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@nl
prefLabel
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@ast
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@en
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@nl
P2093
P2860
P1476
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109
@en
P2093
Alexandra Hockla
Derek C Radisky
Evette S Radisky
P2860
P2888
P356
10.1007/S10549-009-0699-0
P407
P577
2009-12-25T00:00:00Z
P5875
P6179
1005933981